- The FDA is set to reclassify hydrocodone-based painkillers as Schedule II substances (up from Schedule III) to reflect their potential for abuse.
- What it means (practically speaking): Refills would be limited to a 90-day supply as opposed to 180 days.
- Companies that make either brand name or generic versions: AbbVie (ABBV), Actavis (ACT), Teva (TEVA), Mallinckrodt (MNK).
FDA gets tougher on hydrocodone in effort to battle abuse
Oct 25 2013, 09:26 ET